Literature DB >> 14709834

Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism.

Gurcan Kisakol1, Ahmet Kaya, Sait Gonen, Recep Tunc.   

Abstract

Bone turnover is reported to increase in favour of resorption in overt hyperthyroidism and the rate of resorption is associated with the levels of thyroid hormones. Hypothyroidism, on the other hand, was shown to cause no disturbance of calcium kinetics and found to associate lower trabecular resorption surfaces and increased bone cortical thickness. Similar studies are very rare in subclinical thyroid disorders and consequently we aimed to examine calcium and bone metabolism in subclinical thyroid disorders. Thirteen patients with subclinical hyperthyroidism secondary to untreated Graves' disease, 20 patients with subclinical hypothyroidism and 10 healthy subjects participated in this survey. Briefly calcium, phosphorus, and creatinine (Cre), urinary deoxypyridinoline (U-DPD) and serum osteocalcin (OC) were measured as biochemical markers for calcium metabolism. Concerning serum Ca and phosphorus levels, there were no differences between three of the groups, but urinary Ca excretion was higher in subclinical hyperthyroid patients compared to control and hypothyroid subjects. Hypothyroid patients had similar U-DPD levels with control subjects (p = 0.218). Serum OC and U-DPD were higher in subclinical hyperthyroid compared to control subjects (p<0.001 and p<0.001 respectively). We demonstrated a higher bone turnover and greater calcium excretion in subclinical hyperthyroid patients. Additionally, we found that subclinical hypothyroidism is not associated with disturbed calcium metabolism. As persistent increase in bone turnover is responsible for accelerated bone loss, patients with Graves' disease may have increased risk for osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14709834     DOI: 10.1507/endocrj.50.657

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  11 in total

1.  ENA Actimineral Resource A restores bone loss and bone quality in ovariectomized rats.

Authors:  Sun Hee Do; Sung-Yong Hwa; Won-Il Jeong; Ji-Won Lee; Hyun-Jung Kim; In-Seon Lee; Kyu-Shik Jeong
Journal:  Mol Cell Biochem       Date:  2006-07-13       Impact factor: 3.396

2.  Thyroid-stimulating hormone, thyroid hormones, and bone loss.

Authors:  Mone Zaidi; Terry F Davies; Alberta Zallone; Harry C Blair; Jameel Iqbal; Surinder S Moonga; Jeffrey Mechanick; Li Sun
Journal:  Curr Osteoporos Rep       Date:  2009-07       Impact factor: 5.096

Review 3.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

4.  Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study.

Authors:  Sarah C Oltmann; Andrew V Brekke; David F Schneider; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-09-12       Impact factor: 5.344

5.  Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism.

Authors:  S Buscemi; S Verga; S Cottone; G Andronico; L D'Orio; V Mannino; D Panzavecchia; F Vitale; G Cerasola
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

6.  Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men.

Authors:  El Hadidy M El Hadidy; Mohamed Ghonaim; Soma Sh Abd El Gawad; Mohamed Abou El Atta
Journal:  BMC Endocr Disord       Date:  2011-08-06       Impact factor: 2.763

7.  Do premenopausal hypothyroid women on levothyroxine therapy need bone status monitoring?

Authors:  Ruby P Babu; Alap Christy; Anupama Hegde; Poornima Manjrekar; Vivian D'Souza
Journal:  Clin Med Insights Womens Health       Date:  2015-03-15

Review 8.  Expanding the Role of Thyroid-Stimulating Hormone in Skeletal Physiology.

Authors:  Ramkumarie Baliram; Rauf Latif; Mone Zaidi; Terry F Davies
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-03       Impact factor: 5.555

Review 9.  β-Arrestin 1 in Thyrotropin Receptor Signaling in Bone: Studies in Osteoblast-Like Cells.

Authors:  Alisa Boutin; Marvin C Gershengorn; Susanne Neumann
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-20       Impact factor: 5.555

10.  An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born <28 weeks' gestation: results of the TIPIT trial.

Authors:  Sze M Ng; Mark A Turner; Carrol Gamble; Mohammed Didi; Suresh Victor; Donal Manning; Paul Settle; Richa Gupta; Paul Newland; Alan Michael Weindling
Journal:  Trials       Date:  2013-07-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.